IRCT2016120720514N6已完成2 期
Evaluation of safety, efficacy and durability of PDO thread lift- EVE & NU series (product of Meditronic Dongjun CO) for facial rejuvenation: An open label, phase 2, before- after, clinical trial.
Aftab Froozan Arya Organization0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 years 至 60 years(—)
- 性别
- All
入选标准
- •Male and female subjects 30-60 years old; willing to lift the face or eyebrow or improvement the nasolabial folds; providing written informed consent and attendance in follow up session. Exclusion criteria: History of any rejuvenated procedure during last years in face area; history of any Botulinum, laser, or intense pulsed light during last 6 month; history of Isotretinoin during last 3 month; collagen vascular disease; any systemic or topical disorders which interfere with process of wound healing; history of any implant in face area; severe cardiac disease or cardiac pacemaker; any active, chronic and recurrent infection; bleeding disorders, coagulopathy, any drugs affect bleeding time; susceptibility to keloids or scar formation; active smoker ( last 2 years); pregnancy/ breast feeding
排除标准
- 未提供
研究者
相似试验
已完成
4 期
Self-administered fentanyl for birthing women.ChildbirthReproductive Health and Childbirth - Childbirth and postnatal careACTRN12609000006246Western Health50
招募中
4 期
The study to evaluate the efficacy and safety of Polynucleotide on Acne ScarsPolynucleotide, Acne scarAcne scarTCTR20230213003SW HEALTHCARE CO.,LTD27
招募中
4 期
The study to evaluate the efficacy and safety of Polynucleotide for Facial Rejuvenation in ThailandHealthyPolynucleotide, Facial RejuvenationTCTR20230213002SW HEALTHCARE CO.,LTD25
招募中
4 期
The study to evaluate the efficacy and safety of Polynucleotide for Periorbital Rejuvenation in ThailandHealthyPolynucleotide, Periorbital RejuvenationTCTR20230214003SW HEALTHCARE CO.,LTD25
已完成
3 期
A clinical trial to study the effect of primaquine conventional release tablet and primaquine sustained release tablet in prevention of relapse of plasmodium vivax malaria.CTRI/2010/091/000245Ipca Laboratories Ltd360
